In spite of its potential importance ([@bib14]; [@bib18]; [@bib19]) there is currently no uniform approach to measuring the timeliness of cancer diagnosis. The time between the first symptomatic presentation of a cancer patient to a general practitioner and their first specialist referral for further investigation (i.e., the 'primary care interval\') is a relatively established measure ([@bib1]; [@bib10]; [@bib7]; [@bib20]). The number of consultations with a general practitioner before hospital referral is increasingly being used as a measure of the promptness of cancer diagnosis ([@bib12]; [@bib13]; [@bib15]; [@bib17]; [@bib2]; [@bib9]; [@bib16]).

Both measures (i.e., both the primary care interval and the number of pre-referral consultations) have specific strengths and weaknesses, some of which are shared (see [Online Supplementary Information, Table](#sup1){ref-type="supplementary-material"}). Exploring whether and how the two measures are associated is important: If strongly correlated, both or either can be used for research and quality surveillance; if weakly correlated, using the number of pre-referral consultations as a measure of timeliness should be discouraged. Importantly, if the number of pre-referral consultations is a valid surrogate of the primary care interval, earlier diagnosis efforts could focus on improving the sensitivity of symptom appraisal by general practitioners during a medical consultation, for example, using clinical decision support tools ([@bib6]; [@bib8]). We therefore examined the association between the number of pre-referral consultations and the primary care interval.

Materials and Methods
=====================

We analysed data from the (English) National Audit of Cancer Diagnosis in Primary Care (2009--2010), undertaken as part of the National Awareness and Early Diagnosis Initiative ([@bib4]; [@bib15]). Data were collected by general practitioners or other professionals in an estimated total of 1170 general practices (∼14% of all practices in England) who participated voluntarily. Comparisons with cancer registration statistics indicate good representativeness ([@bib15]). We analysed data on patients aged 15 years or older with completely observed information on number of pre-referral consultations and primary care interval values from 0 to 730 days. Because of sample size considerations, analysis was restricted to patients with the 18 most numerous cancers.

We calculated the median primary care interval (in days) and inter-quartile range for different numbers of pre-referral consultations. This was done both for all patients and separately by cancer. Box plots were used to further illustrate these data. Given the right-skewed nature of primary care interval data, we calculated the Spearman\'s rank correlation co-efficient of the two measures. Subsequently, we calculated the receiver--operator characteristic (ROC) area under the curve (AUC), treating the primary care interval as a continuous variable and the number of pre-referral consultations as a binary variable ('three or more\' *vs* 'one or two\' consultations---as used by UK policy makers [@bib11]).

Using linear regression we explored whether the association between the two measures varied between different patients groups. Owing to data non-normality, significance testing was based on bootstrapping (1000 samples). See also [Online Supplementary Information](#sup1){ref-type="supplementary-material"}.

Results
=======

Among 13 035 patients included in the analysis the median (inter-quartile range) primary care interval was 5 (0--23) days. Most (82%) were referred after 1 (57.5%) or 2 (24.6%) consultations, with median primary care interval (inter-quartile range) of 0 (0--3) and 15 (7--31) days, respectively. Of the 18% that required 3 (9.2%), 4 (3.9%) or '5 or more\' (4.8%) consultations, the median primary care interval (inter-quartile range) was 34 (16--64), 47 (27--90) and 97 (46--173) days, respectively ([Table 1](#tbl1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). Similar patterns were observed for patients with any of the 18 cancers ([Table 1](#tbl1){ref-type="table"}). Patients with multiple myeloma and lung cancer had high proportions of three or more pre-referral consultations (46% and 33%, respectively) and long median primary care intervals (21 and 14 days, respectively). Patients with breast cancer and melanoma had the lowest proportion of three or more pre-referral consultations (3% and 5%, respectively) and the shortest median primary care intervals (0 days for both).

For patients with any of the 18 cancers the Spearman\'s *r* was 0.70 (*P*\<0.0001) and the ROC AUC was 0.88 (95% confidence interval: 0.87--0.89) ([Table 2](#tbl2){ref-type="table"}). Primary care interval cutoff values of either 17 or 18 days have sensitivity and specificity of 0.80 or higher for predicting pre-referral consultation category.

Using linear regression we found no evidence for interactions between the number of pre-referral consultations and age, sex or ethnicity (*P*=0.998, *P*=0.261 and *P*=0.691, respectively), but strong evidence for interaction with cancer type (*P*\<0.001). Nevertheless, the association was at least moderately strong for each cancer (Spearman\'s *r* range: from 0.55 to 0.77 for prostate and brain cancer, respectively, [Table 2](#tbl2){ref-type="table"}). There was evidence for an interaction between the number of pre-referral consultations and different referral types (*P*=0.016), however the association was strong for any referral type (Spearman\'s *r* range: from 0.67 to 0.72 for routine and '2-week\' referrals, respectively, [Table 2](#tbl2){ref-type="table"}). See also [Online Supplementary Information](#sup1){ref-type="supplementary-material"}.

Discussion
==========

Using data from the English National Audit of Cancer Diagnosis in Primary Care we found that the number of pre-referral consultations has construct validity as a measure of the primary care interval. The association between the two measures was strong for patients with any type of hospital referral and either moderate or strong for patients with any of the studied cancers. Patients with cancers requiring greater number of consultations tended to have longer primary care intervals (e.g., multiple myeloma) and vice versa (e.g., breast cancer).

The findings allow us to gain some insight into the potential reduction in primary care interval that could be achievable by reducing the number of pre-referral consultations. For example, the median primary care interval for patients with 'five or more\' pre-referral consultations was 49.5, 62.5 and 81.5 days longer than those with four, three and two consultations, respectively. Such gains in the timeliness of diagnosis could potentially be achievable if patients with different number of consultations present with similar symptoms. These illustrations should therefore be considered to represent the theoretical maximum potential for improvement (in timeliness that could be achievable by reducing the number of pre-referral consultations) given the state of medical knowledge and system factors at the time of the audit period (such as the extent of access to specialist investigation available to general practitioners).

A correlation between pre-referral consultations and duration of primary care interval might be intuitive but evidence about this association is sparse ([@bib3]). The findings corroborate evidence suggesting that suspecting the diagnosis of cancer is generally more challenging for cancers without specific symptoms (e.g., multiple myeloma, stomach cancer) compared with cancers with specific signs and symptoms (breast cancer, melanoma) ([@bib15]; [@bib9]).

Strengths of our study include its large sample size, the inclusion of patients with 18 different cancers and the use of a range of analytical approaches. There are several weaknesses. Some consultations may have been misclassified, either because of poor recording of presenting symptoms or misattribution of recorded symptoms---particularly in the context of co-morbidity ([@bib20]). However, we judge that such errors are unlikely to have introduced substantial bias. Although there was no independent validation of the audit data, patients responding to the (2010) Cancer Patient Experience Survey reported similar patterns of variation by cancer in relation to the number of pre-referral consultations ([@bib9]). Considering generalisability, although patients included in the audit reflect national incidence statistics in respect of cancer type, age and sex ([@bib15]), it is conceivable that organisational factors and care quality in participating practices were different to other (non-participating) practices. Finally, we could not examine whether any of the prolonged values of either the primary care interval or the number of pre-referral consultations were either justifiable or preventable.

A more liberal policy for referral and investigation of patients with non-specific symptoms may increase the number of cancer patients diagnosed after one or two consultations; but at the expense of additional patient anxiety and healthcare utilisation costs for patients who will be investigated but found not to have cancer. Wider access by general practitioners to specialist diagnostic tests is increasingly being advocated ([@bib5]). There is a need to monitor the impact of general practitioner-led investigations on the promptness of diagnosis of cancer (and other pathologies) and on resource use. This can be achieved by a programme of primary care audit that encompasses use of diagnostic imaging or endoscopic investigations. Point-Of-Care diagnostic technologies can also have a part in reducing the number of consultations before referral, and such tests merit further development and evaluation.

The findings support efforts to improve the timeliness of diagnosis by improving the sensitivity of the appraisal of cancer symptoms by general practitioners, for example, using clinical decision support tools ([@bib6]; [@bib8]). Raising awareness of the importance of persistent symptoms among patients may also help reduce between-consultation intervals (and therefore improve timeliness of diagnosis), although such improvements may not necessarily reduce the number of pre-referral consultations. Research and policy initiatives can be further prioritised, focusing on patients with cancers that are more 'difficult-to-suspect\' because of poor symptom specificity (e.g., multiple myeloma, lung, stomach and pancreatic cancer), which are typically associated with longer primary care intervals and greater number of pre-referral consultations ([@bib9]).

In conclusion, both the number of pre-referral consultations and primary care interval are important measures of the timeliness of cancer diagnosis and are inter-related. Improving the sensitivity of symptom appraisal by general practitioners to detect cancer symptoms should be prioritised by research and policy initiatives. Development and evaluation of interventions can particularly focus on patients with difficult-to-suspect cancers.
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###### 

Click here for additional data file.

![Box plot for primary care interval by category of number of pre-referral consultations (1, 2, 3, 4 and '5+\') for patients with any of 18 cancers (*n*=13 035).](bjc20131f1){#fig1}

###### Median primary care interval (number of days) and inter-quartile range by pre-referral consultations category (*n*=13 035)

                                                                   **Median primary care interval by number of pre-referral consultations category (1***--***5+)**                                                                                             
  -------------------------- -------- ------- --------- --------- ------------------------------------------------------------------------------------------------- --------- ---------- ---------- ---------- ---------- ---------- ------------- ----------- -------------
  ***All patients***         13 035   17.9    **5**     0--23                                                   **0**                                               0--3        **15**   7--31        **34**   16--64       **47**   27--90         **96.5**   46--172.5
  **By cancer**                                                                                                                                                                                                                                                
  **Multiple myeloma**       176      46.0    **21**    5--55                                                   **1**                                               0--12       **14**   5--33        **38**   21--64       **45**   22--82          **82**    34--129
  **Unknown primary**        136      41.2    **14**    0--37.5                                                 **0**                                               0--3        **19**   9--30        **24**   13--42      **26.5**  16--62          **54**    37--124
  **Stomach**                237      32.1    **14**    0--57                                                   **0**                                               0--4.5      **21**   9--42       **28.5**  16--69.5     **66**   32--123         **127**   82--194
  **Lung**                   1421     32.8    **14**    3--40                                                   **3**                                               0--10       **13**   6--27        **30**   14--56.5     **39**   23--70          **73**    42--140
  **Renal**                  272      22.1    **12**    1--37                                                   **1**                                               0--12.5    **14.5**  7--31        **30**   15--55       **48**   41.5--85        **113**   63--185
  **Prostate**               2201     15.2    **12**    3--28                                                   **4**                                               0--13       **15**   7--28        **38**   20--77      **66.5**  36.5--188.5     **113**   38--181
  **Lymphoma**               590      25.8    **9**     0--32                                                   **1**                                               0--5        **14**   7--28        **32**   14--69      **42.5**  25.5--84       **76.5**   41--189
  **Pancreatic**             303      31.4    **8**     1--35                                                   **0**                                               0--4        **8**    4--14        **21**   13--41      **45.5**  16--86          **93**    49--144
  **Ovarian**                324      27.8    **8**     0--27                                                   **0**                                               0--5        **11**   5--21       **39.5**  14--54       **36**   13--49          **49**    25--71
  **Oesophageal**            500      22.6    **7**     0--33                                                   **0**                                               0--1        **20**   8--37        **33**   21--56       **76**   43--124        **119.5**  61--245
  **Colorectal**             1999     21.3    **7**     0--32                                                   **0**                                               0--3.5      **18**   7--40        **39**   15--75.5     **56**   30--114         **122**   56--203
  **Leukaemia**              358      17.6    **6.5**   0--23                                                   **1**                                               0--6        **15**   7--37        **33**   13--52      **32.5**  9--66           **25**    14--98
  **Oropharyngeal**          178      21.9    **6**     0--27                                                   **0**                                               0--3       **17.5**  12--33.5     **28**   18--57      **42.5**  29--57          **64**    35--116
  **Brain**                  159      21.4    **4**     0--19                                                   **0**                                               0--1.5      **7**    5--16       **25.5**  5--64        **30**   22--62         **74.5**   49--166
  **Bladder**                721      14.6%   **4**     0--18                                                   **0**                                               0--3        **12**   7--22.5      **22**   16--61.5     **59**   43--141        **153.5**  73--297
  **Endometrial**            358      9.8     **1**     0--19                                                   **0**                                               0--2        **21**   8--44.5      **41**   19--63      **70.5**  26.5--96.5      **258**   164--349
  **Melanoma**               735      5.4     **0**     0--6                                                    **0**                                               0--1        **30**   11--53      **37.5**  22--95       **42**   31.5--106.5     **100**   67--141.5
  **Breast**                 2367     2.9     **0**     0--1                                                    **0**                                               0--0        **14**   7--28        **34**   17--75       **44**   21--71         **115.5**  85--145
  **By referral type**                                                                                                                                                                                                                                         
  **'Routine\'**             2030     24.4    **13**    1--42                                                   **1**                                               0--7        **20**   8--42       **45.5**  20--82       **75**   42--141        **113.5**  62.5--207
  **'Other\'**               1122     19.1    **5**     0--26                                                   **0**                                               0--5        **14**   7--29        **35**   13--77       **63**   34--83          **89**    54--180
  **'Emergency\'**           1642     25.9    **4**     0--21                                                   **0**                                               0--2        **8**    3--19        **21**   11--46       **35**   16--71          **56**    30--128
  **'Two-week\' referral**   824      14.5    **3**     0--20                                                   **0**                                               0--2        **15**   7--31        **35**   19--63       **45**   28--85         **103.5**  52.5--169.5

###### Spearman\'s rank correlation co-efficient and ROC AUC values for the association between primary care interval and category of number of pre-referral consultations (*n*=13 035)

                              ***N***   **Spearman\'s** ***r***   **Spearman\'s** ***r P-*****value**   **ROC area under the curve**[a](#t2-fn2){ref-type="fn"}   **ROC area 95% lower CI**   **ROC area 95% upper CI**
  -------------------------- --------- ------------------------- ------------------------------------- --------------------------------------------------------- --------------------------- ---------------------------
  ***All patients***           13035           **0.70**                        \<0.0001                                        **0.88**                                     0.87                        0.89
  **By cancer**                                                                                                                                                                              
  **Breast**                   2367            **0.56**                                                                        **0.96**                                     0.93                        0.98
  **Prostate**                 2201            **0.55**                                                                        **0.84**                                     0.82                        0.86
  **Colorectal**               1999            **0.71**                                                                        **0.86**                                     0.84                        0.88
  **Lung**                     1421            **0.62**                                                                        **0.83**                                     0.81                        0.86
  **Melanoma**                  735            **0.61**                                                                        **0.87**                                     0.81                        0.94
  **Bladder**                   721            **0.72**                                                                        **0.90**                                     0.87                        0.93
  **Lymphoma**                  590            **0.70**                                                                        **0.87**                                     0.84                        0.90
  **Oesophageal**               500            **0.75**                                                                        **0.87**                                     0.84                        0.91
  **Endometrial**               358            **0.64**           \<0.0001[b](#t2-fn3){ref-type="fn"}                          **0.89**                                     0.84                        0.94
  **Leukaemia**                 358            **0.59**                                                                        **0.81**                                     0.76                        0.87
  **Ovarian**                   324            **0.68**                                                                        **0.86**                                     0.82                        0.91
  **Pancreatic**                303            **0.71**                                                                        **0.89**                                     0.85                        0.93
  **Renal**                     272            **0.60**                                                                        **0.84**                                     0.79                        0.90
  **Stomach**                   237            **0.76**                                                                        **0.88**                                     0.83                        0.92
  **Oropharyngeal**             178            **0.72**                                                                        **0.85**                                     0.79                        0.91
  **Multiple myeloma**          176            **0.73**                                                                        **0.88**                                     0.83                        0.93
  **Brain**                     159            **0.77**                                                                        **0.92**                                     0.87                        0.96
  **Unknown primary**           136            **0.76**                                                                        **0.87**                                     0.81                        0.93
  **By referral type**                                                                                                                                                                       
  **'Two-week\' referral**     8241            **0.72**                                                                        **0.89**                                     0.88                        0.90
  **'Emergency\'**             1642            **0.72**           \<0.0001[b](#t2-fn3){ref-type="fn"}                          **0.88**                                     0.87                        0.90
  **'Routine\'**               2030            **0.67**                                                                        **0.85**                                     0.83                        0.87
  **'Other\'**                 1122            **0.67**                                                                        **0.88**                                     0.85                        0.90

Abbreviations: AUC=area under curve; CI=confidence interval; ROC=receiver--operator characteristic.

For this analysis, the number of pre-referral consultations was dichotomised into 3+ *vs* 1--2 pre-referral consultation categories. Sensitivity analysis indicated that ROC AUC values were similar when other binary outcomes (e.g., '2+\' *vs* 1, or '4+\' *vs* 1, 2 or 3) were used, see [Online Supplementary Information](#sup1){ref-type="supplementary-material"}.

For any cancer type, and for any referral type.
